【摘要】 目的:评价阿司匹林预防肺癌发生的疗效,为临床实践和研究提供参考和依据。方法:通过检索中国生物医学文献数据库、中国学术期刊网络出版总库、PudMed和EMbase等国内外权威的数据库,全面收集相关的临床研究,按纳入排除标准筛选文献并收集相关数据和信息,采用Rev Man 5.0统计软件进行Meta分析,并对性别、阿司匹林剂量和疗程等进行亚组分析。结果:共纳入17个临床研究,Meta分析显示,使用阿司匹林者较未使用者肺癌的发生率较低,OR=0.82,95%CI:0.72~0.94。亚组分析显示,低剂量阿司匹林(≤100mg)可能较高剂量阿司匹林(>100mg)效果好,OR及其95%CI分别为0.94(0.81~1.09)和1.01(0.87~1.16);长期服用阿司匹林能降低肺癌发病,服用≤1年、>1~<5年、≥5年与肺癌发生关系的OR值及其95%CI,分别为1.06(0.94~1.20)、0.73(0.57~0.94)和0.73(0.57~0.93)。结论:低剂量(≤100mg)长期(>1年)使用阿司匹林在降低肺癌发病方面收益更大。由于本Meta分析纳入的为观察性临床研究,所以将来有必要开展多中心大样本的随机对照试验来进一步证实。更多还原

【Abstract】 OBJECTIVE:To evaluate the clinical preventive efficacy of aspirin for lung cancer,and to provide reference and evidence for clinical practice and research.METHODS:To search relevant clinical researches by authorized databases such as Chinese BioMedical Literature Database(CBM),Chinese National Knowledge Infrastructure(CNKI),PudMed,EMbase and so on.Selecting studies based on inclusion and exclusion criterion and extracting data and information.The data and information were used to perform Meta-analysis by Rev Man 5.0and subgroup-analyses were conducted through gender,the dose and duration of aspirin treatment and so on.RESULTS:A total of 17clinical researches were included.Meta-analysis showed that aspirin could reduce the risk of lung cancer,OR=0.82,95%CI:0.72-0.94.Subgroup analysis showed that low-does aspirin(≤100mg)had more protective effects than high-does aspirin(>100mg).OR=0.94,95%CI:0.81-1.09and OR=1.01,95%CI:0.87-1.16.Long-term use of aspirin showed significantly protective effect(1-5years,OR=0.73,95%CI:0.57-0.94and≥5years,OR=0.73,95%CI:0.57-0.93),but short-term was(OR=1.06,95%CI:0.94-1.20).CONCLUSIONS:The Meta-analysis shows low dose and long-term use of aspirin may significantly reduce the risk of lung cancer,low dose and longterm use of aspirin may significantly reduce the risk of lung cancer.Multi-center big sample randomized controlled trial should be conducted to approve the result in the future,because the meta-analysis includes observational studies.更多还原